UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus

Nature communications, 2024-05, Vol.15 (1), p.4350-4350, Article 4350

2024

Volltextzugriff (PDF)

GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus

npj vaccines, 2023-05, Vol.8 (1), p.73-73, Article 73

2023

Volltextzugriff (PDF)

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

npj vaccines, 2024-08, Vol.9 (1), p.143-15, Article 143

2024

Volltextzugriff (PDF)

Rhabdoviruses as vectors for vaccines and therapeutics

Current opinion in virology, 2020-10, Vol.44, p.169-182

2020

Volltextzugriff (PDF)

Development of Rhabdoviral-Based Crimean-Congo Hemorrhagic Fever Virus Vaccines

Scher, Gabrielle

2023

Volltextzugriff (PDF)

Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates

The Journal of infectious diseases, 2021-09, Vol.224 (6), p.995-1004

2021

Volltextzugriff (PDF)

TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.921-936.e1

2023

Volltextzugriff (PDF)

mRNA-LNP vaccine-induced CD8+ T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies

Molecular therapy, 2024-06, Vol.32 (6), p.1790-1804

2024

Volltextzugriff (PDF)

Thymine DNA Glycosylase (TDG) is involved in the pathogenesis of intestinal tumors with reduced APC expression

Oncotarget, 2017-10, Vol.8 (52), p.89988-89997

2017

Volltextzugriff (PDF)

Isotopic interrogation of a suspected late Eocene glaciation

Paleoceanography, 2014-06, Vol.29 (6), p.628-644

2014

Volltextzugriff (PDF)

Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e24174-e24174

2020

Volltextzugriff (PDF)

c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.5045-5045

2018

Volltextzugriff (PDF)

Methylphenidate for fatigue in ambulatory men with prostate cancer

Cancer, 2010-11, Vol.116 (21), p.5102-5110

2010

Volltextzugriff (PDF)

Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5093-TPS5093

2016

Volltextzugriff (PDF)

Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.5034-5034

2017

Volltextzugriff (PDF)

Chimeric antigen receptor (CAR + ) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS3115-TPS3115

2013

Volltextzugriff (PDF)

Chimeric antigen receptor (CAR + ) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)

Journal of clinical oncology, 2013-02, Vol.31 (6_suppl), p.72-72

2013

Volltextzugriff (PDF)

A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4548-4548

2012

Volltextzugriff (PDF)

Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study

Journal of clinical oncology, 2012-02, Vol.30 (5_suppl), p.43-43

2012

Volltextzugriff (PDF)

A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS4697-TPS4697

2012

Volltextzugriff (PDF)

Isotopic interrogation of a suspected late Eocene glaciation: hidden glaciation revealed in the Eocene

Paleoceanography, 2014-06, Vol.29 (6), p.628-644

2014

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(18)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)
Dissertationen
(1)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(9)
Npj Vaccines
(2)
Paleoceanography
(2)
Cancer
(1)
Current Opinion In Virology
(1)
Gastroenterology
(1)
Molecular Therapy
(1)
Nature Communications
(1)
Oncotarget
(1)
Paleoceanography And Paleoclimatology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus

GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease

Rhabdoviruses as vectors for vaccines and therapeutics

Development of Rhabdoviral-Based Crimean-Congo Hemorrhagic Fever Virus Vaccines

Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates

TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype

mRNA-LNP vaccine-induced CD8+ T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies

Thymine DNA Glycosylase (TDG) is involved in the pathogenesis of intestinal tumors with reduced APC expression

Isotopic interrogation of a suspected late Eocene glaciation

Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)

c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study

Methylphenidate for fatigue in ambulatory men with prostate cancer

Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC)

Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy

Chimeric antigen receptor (CAR + ) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)

Chimeric antigen receptor (CAR + ) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)

A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)

Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study

A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC)

Isotopic interrogation of a suspected late Eocene glaciation: hidden glaciation revealed in the Eocene

Suchergebnisse filtern